NL-OMON44381
Completed
Not Applicable
Open label, randomized, cross-over study to explore the pharmacokinetics of BAY 1834845 after oral and intravenous dosing, including food effect and absolute bioavailability (Part A), and to investigate the effect of BAY 1834845 on the pharmacokinetics of orally administered methotrexate (Part B) in healthy male subjects - BAY 1834845 FE, BA, Methotrexate DDI Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Rheumatoid arthritis
- Sponsor
- Bayer AG
- Enrollment
- 22
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- healthy male subjects
- •\- 18 \- 50 years, inclusive
- •\- BMI: 18\.0 \- 30\.0 kg/m², inclusive
Exclusion Criteria
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 3 months before the start of this study. In case of donating more than 0\.5 liters of blood in the 4 week prior the start of this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
A randomised, open-label, cross-over study to examine the pharmacokinetics, and short-term safety and efficacy of two dosing strategies of raltegravir plus atazanavir in human immunodficiency virus (HIV)-infected patientschronic HIV infectionInfection - Acquired immune deficiency syndrome (AIDS / HIV)ACTRN12609000179235ational Centre in HIV Epidemiology/The University of New South Wales24
Withdrawn
Not Applicable
An open-label, randomized, crossover study to evaluate the pharmacokinetics, bioavailability, and bioequivalence following administration of JZP-507 oral solution and Xyrem®in healthy subjects.cataplexynarcolepsy10040998NL-OMON45490Jazz Pharmaceuticals60
Completed
Not Applicable
Drug-drug Interaction Study(Lobeglitazone, Warfarin)Endocrine, nutritional and metabolic diseaseKCT0000999Chong Kun Dang24
Completed
Phase 1
To estimate the bioavailability (amount of drug which reaches the blood) of GRC 17536 following oral administration in normal healthy male adults.CTRI/2014/12/005320Glenmark Pharmaceuticals SA60
Active, not recruiting
Not Applicable
Patient preferences for Eucreas® versus Victoza® in Type 2 Diabetes mellitus patientstype 2 diabetes mellitusMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2011-003818-16-DEovartis Pharma GmbH